Federal award (PURCHASE ORDER, fiscal year 2021)
Recipient: CMC PHARMACEUTICALS, INC.
Awarding agency: Department of Defense / U.S. Special Operations Command
Funding agency: Department of Defense / U.S. Special Operations Command
Period of performance: 2022-01-24 to 2022-07-25
Current total value of award: $149345.28
Description: FEASIBILITY STUDY, SBIR PHASE I, TOPIC SOCOM213- 002, CONCENTRATED ATROPINE SULFATE FORMULATIONS